NLBIF - Mydecine Innovations Group Subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) — NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of  Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:NLBIF)(FSE:0NF) (“Mydecine” or the “Company”) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securing non-dilutive funding opportunities globally.

NeuroPharm™ is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations including Veterans, emergency medical services personnel and other high-risk constituencies. In collaboration with its strategic partners, NeuroPharm is deploying evidence-based medicine in the establishment of psilocybin-based therapies addressing the unmet needs of high-risk constituents. ...